


Main Indicators

Pharmaceutical Expenditure

September 2014

Public pharmaceutical expenditure. Retail market (monthly evolution)


In July 2014, the 12 months expenditure has been lower than the historical peak in 3,432 €M. (-27,0%)



Source: Farmaindustria + MoH

Public pharmaceutical expenditure. Total and innovative products


Total public pharmaceutical expenditure and in medicines subject to rebates (innovations) Retail market. Annual growth rate



Public pharmaceutical expenditure in innovations (orange) behaves much worse than total public pharmaceutical expenditure (green)

Source: Farmaindustria + MoH

Compared evolution of total public pharmaceutical expenditure and medicines subject to rebates (innovations) Retail market. 12 months accumulated values. Index May 2011=100




Public pharmaceutical expenditure in innovations (orange) keeps a slightly decreasing profile from June 2013

Source: Farmaindustria + MoH


Public pharmaceutical expenditure (actual and forecasts)

Public pharmaceutical expenditure in NHS prescriptions (€ Mill.)




Source: 2013-2010 data, MoH, Farmaindustria and INE. Forecasts 2014-2015, Farmaindustria + INE

Public pharmaceutical expenditure in hospitals (€ Mill.)



Source: 2013-2010 data, MoH, Farmaindustria (Hospital survey) 2014-15 forecasts, Farmaindustria according to IMS forecasts (Market Prognosis Spain, rev. March 2014)


Total public pharmaceutical expenditure in NHS prescriptions + hospitals (€ Mill.)



Source: 2013-2010 data, MoH, Farmaindustria (Hospital survey) 2014-15 forecasts, Farmaindustria according to IMS forecasts (Market Prognosis Spain, rev. March 2014)

Public pharmaceutical expenditure. Per capita and % GDP

Public pharmaceutical expenditure in NHS prescriptions + hospitals (€ per capita)



Public pharmaceutical expenditure per capita (292.5 € = 194.9 € + 97.6 €) is 22% below the Eurozone




Source: 2013-2010 data, MoH, Farmindustria and INE. Forecasts 2014-2015, Farmindustria + INE

Public pharmaceutical expenditure as a share of GDP (1.35% = 0.9% + 0.45%) is now below the Eurozone, even in bailed out countries.




Public pharmaceutical expenditure in NHS prescriptions + hospitals (%GDP)



Source: 2013-2010 data, MoH, Farmindustria and INE. Forecasts 2014-2015, Farmindustria + INE+ Spanish Government, Stability Program update 2014-2017 (p. 21)

Public pharmaceutical expenditure. Retail market (i)

Public pharmaceutical expenditure. Retail market.
(€ per cápita)




Public pharmaceutical expenditure per capita in the retail market in 2013 (194,9 €) was similar to that of 2002 (11 years before)

Source: Farmaindustria using information from MSSSI and INE

Public pharmaceutical expenditure as % GDP in the retail market in 2013 (0,9%) was similar to that of 1993 (20 years before)


Public pharmaceutical expenditure. Retail market
% GDP



Source: Farmaindustria using information from MSSSI, Eurostat and INE

Public pharmaceutical expenditure. Retail market (ii)

Public pharmaceutical expenditure. Retail market.
% Total Public Expenditure




Public pharmaceutical expenditure as % Total Public Expenditure in 2013 (2.0%) was the same as that of 1991 (22 years before)

Source: Farmaindustria using information from MSSSI and Ministry of Economy Estimate for 2013, according to Budget Planning 2014. Kindgom of Spain

Public pharmaceutical expenditure as % of Public Healthcare Expenditure in 2013 (14.5%) was similar to that of 1983 (30 years before)


Public pharmaceutical expenditure. Retail market
% Public Healthcare Expenditure



Source: Farmaindustria using information from MSSSI. Estimates for 2012 and 2013 from the evolution of healthcare public budgets for both years

Trends in the main pharmaceutical markets

Growth of pharmaceutical markets.
2012




In 2012, Spain experienced the greatest decrease of all major pharmaceutical markets

Source: Farmaindustria from IMS Health (World Pharmaceutical Markets Summary)

Note: Retail market (except for Japan that includes hospital market)

2013 data show the negative trend of the Spanish market


Growth of pharmaceutical markets.
2013



Source: Farmaindustria from IMS Health (World Pharmaceutical Markets Summary)

Note: Retail market (except for Japan that includes hospital market)


The gap between public pharmaceutical expenditure per capita in Spain and the average of Euro Area countries is increasing



Source: Farmaindustria from OECD and IMS

Note: 2010 and 2011 data, OCDE. 2012 and 2013 estimates, Farmaindustria using IMS data and forecasts (IMS MIDAS and World Pharmaceutical Markets Summary) applied on actual OECD data (2011)

Market share of all products priced at generics' level. Retail market



Source: Farmaindustria using information from IMS

Note: Total prescription market net of rebates (Royal Decree-laws 8/2010 and 9/2011)